SEC Filing Summary
Filing identity: The supplied filing is Trovagene, Inc.’s Form 10-Q for the quarter ended June 30, 2013, filed August 14, 2013. It does not identify Cardiff Oncology, Inc.; verify that this is the intended filing.
Business context and reporting period
Trovagene described itself as a development-stage molecular diagnostics company developing urine-based cancer monitoring tests using cell-free nucleic acid technology. The unaudited report covers the three and six months ended June 30, 2013, with comparisons to 2012.
Financial results and liquidity
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | $49,000 (2013); $41,500 (2012) | $168,123 (2013); $75,653 (2012) |
| Operating expenses | $2,423,112 (2013); $1,287,019 (2012) | $4,932,074 (2013); $2,451,388 (2012) |
| Net loss attributable to common stockholders | $5,279,475 (2013); $3,435,970 (2012) | $6,396,057 (2013); $4,608,170 (2012) |
| Basic and diluted loss per share | $0.34 (2013); $0.28 (2012) | $0.41 (2013); $0.40 (2012) |
| Cash used in operating activities | Not separately presented | $3,364,625 (2013); $2,201,600 (2012) |
- Revenue consisted only of royalty income; the filing reports no meaningful commercial scale, and gross margin is not presented.
- At June 30, cash and cash equivalents were $8,302,290, down from $10,819,781 at December 31, 2012. Working capital was $7,061,277, versus $10,317,833.
- Total assets were $9,625,066 and total liabilities $12,096,201, resulting in stockholders’ deficiency of $2,471,135. The $10,381,796 derivative liability was primarily warrant-related and measured using significant unobservable inputs (Level 3).
- Debt included $315,168 borrowed under a new equipment facility: $62,993 current and $252,175 long-term. The facility permits up to $1.0 million in equipment borrowing; the company reported covenant compliance.
- Management said cash was expected to fund operations for at least 12 months, but not through successful development and commercialization; further financing would be required.
Changes versus prior comparable periods
- Six-month revenue more than doubled, partly because of additional royalty-bearing agreements and approximately $75,000 of royalties received for prior-year amounts above minimums.
- Six-month R&D expense rose $931,536 to $1,746,094, and G&A expense rose $1,549,150 to $3,185,980, reflecting expanded research, staffing, laboratory investment, and commercialization infrastructure.
- Six-month net loss increased $1,787,007 to $6,380,787 before preferred dividends. A $1,616,168 noncash derivative fair-value loss contributed to the reported loss; the comparable 2012 period also included a derivative fair-value loss of $2,213,315.
- Operating cash use increased by $1,163,025 year over year. Financing cash inflow fell to $1,207,272 from $10,946,605, as the prior-year period included common-stock financing.
Outlook, risks, contingencies, and unusual items
- Management expected R&D and G&A spending to increase as collaborations progressed and commercialization began. It did not provide quantified revenue, earnings, or cash-flow guidance.
- Key stated risks include the time, cost, clinical validation and regulatory review required to develop diagnostic products; competition; and the need to raise capital. Additional equity could dilute shareholders, while debt could impose restrictive covenants. Failure to raise funds could delay, scale back, or end development or commercialization.
- The company announced its first commercial product, a urine-based HPV test, and described progress validating urine-based cancer detection, including an assay for BRAF mutation detection. Clinical work and collaborations included MD Anderson, PerkinElmer, and Illumina.
- PerkinElmer had paid approximately $90,000 in milestone amounts and the company incurred approximately $48,000 of related R&D costs in the quarter. PerkinElmer also held options to negotiate exclusive royalty-bearing licenses in specified fields.
- Subsequent to quarter-end, the company reported July common-stock sales for approximately $15.0 million gross and sales through Cantor Fitzgerald for approximately $4.2 million gross; it also reported approximately $2.6 million from warrant exercises through August 9. These proceeds increased reported August 9 working capital to $28,024,465.
- Disclosure controls and procedures were concluded to be ineffective due to weaknesses in internal control over financial reporting. Management said it was implementing remediation and had introduced an anti-fraud program during the quarter.
- The company reported no material pending legal proceedings and no off-balance-sheet arrangements. It had a potential MultiGen milestone payment of up to $3.7 million, but reported no fair value assigned to that contingent consideration at June 30.
Important facts for investors to verify
- Confirm that Trovagene’s filing, rather than a Cardiff Oncology filing, is the intended document.
- Review subsequent financing proceeds, share issuance, warrant exercises, and resulting dilution against the company’s stated capital needs.
- Assess the assumptions and volatility effects behind the $10.4 million Level 3 derivative liability and related noncash losses.
- Track cash burn, commercialization spending, clinical validation, regulatory requirements, and whether management’s 12-month liquidity assessment remains current.
- Review the disclosed internal-control weaknesses, remediation progress, and any later updates on control effectiveness.